Cancer Immunity and Immunotherapy section concentrates on tumor escape, exclusion, and response biology
Frontiers in Immunology’s Cancer Immunity and Immunotherapy section is built around a tightly defined scientific mission: open-access research on immune-based cancer therapies and tumor immunology. The current slate of articles makes the editorial direction clear. The field is moving beyond broad enthusiasm for immunotherapy and into mechanism-level questions about why some tumors remain invisible to immune attack, why others resist treatment, and which cellular programs can be exploited to restore response.
The newest entries in the section are not clinical trials or regulatory announcements. They are reviews and mini reviews, but they are still clinically consequential because they frame the next round of translational work. Three papers stand out in the listed content: “CXCR2 associated neutrophil stromal interactions and immune exclusion in microsatellite stable colorectal cancer,” “EZH2 at the epigenetic–immune interface: a dual-axis framework for tumor immune evasion and precision combination immunotherapy,” and “Cellular senescence in ovarian cancer: context-dependent effects on tumor immunity and therapy response.” Each title points to a different failure mode in cancer control: exclusion from the tumor microenvironment, epigenetic immune escape, and the shifting role of senescence in treatment sensitivity.
Immune exclusion is not a cosmetic feature of the tumor microenvironment. It is one of the most stubborn reasons immunotherapy underperforms in solid tumors, especially when effector cells never reach the malignant core. The review on microsatellite stable colorectal cancer centers on CXCR2-associated neutrophil stromal interactions, a pairing that suggests a structural barrier rather than a simple absence of immune cells. In practical terms, that kind of biology can leave a tumor surrounded by immune activity at the edges while remaining protected at the center, where meaningful cytotoxic killing must occur.
Epigenetic control moves from background biology to treatment design
The EZH2 review places an epigenetic regulator directly in the path of immune evasion. EZH2 has long been linked to chromatin-level transcriptional control, but the framing here is more ambitious: a “dual-axis” framework connecting tumor immune escape with precision combination immunotherapy. That language signals a field that is no longer satisfied with single-pathway blockade. Instead, investigators are asking whether epigenetic rewiring can alter antigen presentation, T-cell access, and the broader transcriptional state that governs sensitivity to immune pressure.
This matters because immune checkpoint blockade succeeds when the tumor is already poised to be recognized, attacked, or reactivated. When epigenetic programs silence those processes, immune therapy can become biologically underpowered before it begins. EZH2 sits at exactly that interface, where transcriptional repression can shape how a tumor is seen by the immune system and whether a combination regimen has enough biological traction to work.
The treatment logic is straightforward even when the molecular path is not: if a tumor uses epigenetic repression to blunt immune visibility, then the most rational strategy is not only to stimulate immunity but also to reopen the transcriptional state that prevents recognition in the first place. Combination immunotherapy becomes more persuasive when it is built around that kind of mechanism.
Ovarian cancer senescence raises questions about context and timing
The mini review on cellular senescence in ovarian cancer adds another layer of complexity. Senescence can restrain proliferation, but senescent cells also shape the surrounding immune environment, and the effect is not uniformly helpful. The phrase “context-dependent effects” is doing heavy work here. In ovarian cancer, senescence may influence whether immune cells are recruited, excluded, reprogrammed, or diverted into less effective responses.
A one-size-fits-all interpretation of senescence would be misleading. Some senescent programs may create inflammatory cues that help immune surveillance; others may reinforce immune suppression or support therapy resistance through paracrine signaling. The clinical implication is not abstract. If senescence is either helpful or harmful depending on the biological context, then the timing and pairing of therapy become central design choices rather than secondary details.
The section’s broader research agenda favors mechanism over slogans
The surrounding research topics reinforce the same pattern. “Engineering NK-cell engagers and cytokine-armed biologics for cancer therapy” suggests a push toward more precise immune redirection. “AntibodyPlus Therapeutics in Oncology: Innovative Mechanisms, Therapeutic Strategies, and Clinical Advances, Volume II” points to continuing interest in antibody-based platforms with added functional complexity. “Cancer at the crossroads of compromised immunity: prevention, detection, and treatment when the immune system is altered” widens the aperture to patients whose immune systems are already impaired, a population that often falls outside classic immunotherapy assumptions. “Community series in immune cell therapy approaches targeting tumor microenvironment: Volume III” keeps the focus on cellular therapies and the microenvironmental barriers that determine whether those therapies can function.
The throughline is evident. Immuno-oncology is no longer just about activating the immune system; it is about deciding where the immune system is blocked, which tumor programs are hiding the target, and which combinations can reset the interaction. In that sense, the section is mapping the mechanistic bottlenecks that will determine whether immune therapies work in the tumors that still resist them.
One practical consequence stands out. Tumors such as microsatellite stable colorectal cancer and ovarian cancer cannot be understood through a single immune biomarker or a single treatment lever.
The listed articles point instead to layered resistance: stromal barriers, epigenetic repression, and senescence-linked remodeling of the tumor immune milieu. For clinicians and translational investigators, the immediate challenge is to turn those mechanisms into interventions that change response rates rather than simply describe why response fails. The unanswered clinical question is not whether immune therapy matters, but which biological obstacles must be dismantled first in each tumor type before immune therapy can exert its full effect.